SPECIAL REPORT | URN | A sub-study of the landmark clinical trial evaluating the safety and efficacy of the twice-yearly injectable HIV prevention drug, Lenacapavir, has found that it provides 100 percent protection against HIV infection among pregnant and breastfeeding women using it as pre-exposure prophylaxis (PrEP). The Phase 3 …
Read More »
The Independent Uganda: You get the Truth we Pay the Price